MED vs BFAM

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 03, 2026

MED

50.0
AI Score
VS
BFAM Wins

BFAM

64.9
AI Score

Investment Advisor Scores

MED

50score
Recommendation
HOLD

BFAM

65score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric MED BFAM Winner
Forward P/E 12.4844 22.6244 MED
PEG Ratio 0.972 1.76 MED
Revenue Growth -27.6% 6.5% BFAM
Earnings Growth -87.2% -17.0% BFAM
Tradestie Score 50.0/100 64.9/100 BFAM
Profit Margin -8.1% 5.8% BFAM
Beta 1.00 1.00 Tie
AI Recommendation HOLD HOLD Tie

Relative Price Performance (Last 90 Days)

MED 1M: -7.4% · 3M: +6.3% BFAM 1M: -10.7% · 3M: -15.1%

Current Technical Phase

MED

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 48

RSI (14): 47.9 · Price: $11.73

BFAM

Markdown
Sell / avoid

Price below a falling SMA50 (slope -4.3%), weak momentum, RSI 40

RSI (14): 39.8 · Price: $64.26

Fundamentals Snapshot

Metric MED BFAM
Market Cap — —
Forward P/E -41.9 10.9
Trailing P/E — 20.6
Revenue (TTM) — —
Revenue Growth -0.3% 0.1%
Gross Margin 0.7% 0.3%
Operating Margin -0.1% 0.1%
EPS -2.33 3.15
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, BFAM is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.